Qual é o preço para Scilex Holding Company (SCLX)

O preço para Scilex Holding Company (SCLX) é $5.61

Qual é a capitalização de mercado para Scilex Holding Company (SCLX)

A capitalização de mercado para Scilex Holding Company (SCLX) é $47.65M

Scilex Holding Company (SCLX) LPA

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Ano	EPS	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

EPS

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	EPS	Diferença de EPS	País
Eli Lilly and Company LLY.US	$29.85	-	US
Johnson & Johnson JNJ.US	$8.65	-	US
AbbVie Inc. ABBV.US	$3.55	-	US
Roche Holding AG RO.SW	$20.39	-	CH
Merck & Co., Inc. MRK.US	$1.26	-	US

Empresa

EPS

Diferença de EPS

País